#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15262	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2067	734.0	0	.	n	.	0	C1450T	SNP	1450	1450	C	1694	1694	T	840	T,A	760,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15262	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2067	734.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1428	1428	C	937	C	853	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28048	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3481	802.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1660	1660	A	957	A	872	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28048	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3481	802.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2294	2294	C	859	C,T	789,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28048	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3481	802.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2368	2368	A	861	A	802	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28048	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3481	802.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	2920	2920	C	823	C,T	771,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	2168	folP	855	855	100.0	folP.l15.c4.ctg.1	1581	136.7	1	SNP	p	R229S	1	.	.	685	687	AGC	1096	1098	AGC	228;228;226	A;G;C	205;206;202	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5876	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3268	179.1	1	SNP	p	S91F	1	.	.	271	273	TTC	525	527	TTC	198;197;198	T;T;C	178;178;175	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5876	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3268	179.1	1	SNP	p	D95G	1	.	.	283	285	GGC	537	539	GGC	211;210;211	G;G;C	186;182;184	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5876	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3268	179.1	1	SNP	p	G95N	0	.	.	283	285	GGC	537	539	GGC	211;210;211	G;G;C	186;182;184	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	1698	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1284	131.6	1	SNP	p	G45D	0	.	.	133	135	GGC	455	457	GGC	207;209;211	G;G;C	188;187;188	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	884	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	932	94.3	0	.	n	.	0	A197.	DEL	197	197	A	505	505	A	235	A	213	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5172	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2932	175.7	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1512	1514	GTC	210;212;207	G;T;C	193;193;188	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5172	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2932	175.7	1	SNP	p	D86N	0	.	.	256	258	GAC	618	620	GAC	199;197;198	G;A;C	185;182;188	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5172	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2932	175.7	1	SNP	p	R87W	0	.	.	259	261	CGT	621	623	CGT	197;200;197	C;G;T	187;188;182	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5172	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2932	175.7	1	SNP	p	S87R	1	.	.	259	261	CGT	621	623	CGT	197;200;197	C;G;T	187;188;182	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5172	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2932	175.7	1	SNP	p	R87I	0	.	.	259	261	CGT	621	623	CGT	197;200;197	C;G;T	187;188;182	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5172	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2932	175.7	1	SNP	p	S88P	0	.	.	262	264	TCC	624	626	TCC	198;199;199	T;C;C,G	185;186;186,1	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4870	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2498	194.2	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1273	1275	TGC	238;238;237	T;G;C	219;218;216	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4870	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2498	194.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1483	1485	GGC	250;249;251	G;G;C	232;228;230	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	539	4270	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2457	173.4	0	.	p	.	0	R211W	NONSYN	631	633	CGG	1022	1024	TGG	222;222;222	T;G;G	204;205;208	.	.
penA.12.001	penA.12.001	1	1	539	4270	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2457	173.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1322	1324	GCA	245;249;251	G;C;A	219;217;226	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	539	4270	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2457	173.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1325	1327	ATC	252;251;251	A;T;C	227;224;227	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	539	4270	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2457	173.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1337	1339	GTG	254;258;261	G;T;G	230;232;237	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	539	4270	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2457	173.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1337	1339	GTG	254;258;261	G;T;G	230;232;237	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	539	4270	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2457	173.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1841	1843	ACC	245;244;242	A,T;C;C	210,1;216;213	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	539	4270	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2457	173.4	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1895	1897	GCG	225;223;226	G;C,T,A;G	194;179,1,1;190	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	539	4270	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2457	173.4	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1895	1897	GCG	225;223;226	G;C,T,A;G	194;179,1,1;190	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	539	4270	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2457	173.4	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2018	2020	GGC	198;195;197	G;G;C	181;175;174	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	539	4270	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2457	173.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2027	2029	GGC	198;196;195	G;G;C	178;175;173	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	539	4270	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2457	173.4	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2045	2047	TCG	186;185;185	T,G;C;G,C	123,5;142;146,1	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6114	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3032	200.8	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1546	1548	CCG	228;231;232	C;C;G	203;208;202	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2464	porA	1146	1146	99.56	porA.l15.c30.ctg.1	1711	143.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	564	564	C	199	C	173	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	316	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	439	26.1	0	.	p	.	0	V258L	NONSYN	772	774	GTA	106	108	TTA	63;64;64	T;T;A	51;51;51	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	316	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	439	26.1	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	151	153	CAT	58;56;55	C;A;T	49;47;47	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	316	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	439	26.1	0	.	p	.	0	D274S	NONSYN	820	822	GAT	154	156	AGT	54;54;53	A;G;T	47;47;46	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	316	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	439	26.1	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	163	165	TAC	52;52;52	T;A;C	47;47;47	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	316	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	439	26.1	0	.	p	.	0	R307A	NONSYN	919	921	AGA	253	255	GCA	11;11;11	G;C;A	11;11;11	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	316	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	439	26.1	0	.	p	.	0	T311A	NONSYN	931	933	ACA	265	267	GCA	14;14;14	G;C;A	13;13;13	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	316	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	439	26.1	0	.	p	.	0	E312V	NONSYN	934	936	GAA	268	270	GTC	13;13;13	G;T;C	12;12;12	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	316	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	439	26.1	0	.	p	.	0	F314I	NONSYN	940	942	TTC	274	276	ATC	12;12;12	A;T;C	11;11;11	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	316	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	439	26.1	0	.	p	.	0	A316S	NONSYN	946	948	GCG	280	282	TCG	11;10;10	T;C;G	10;10;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	316	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	439	26.1	0	.	p	.	0	V318A	NONSYN	952	954	GTC	286	288	GCC	10;10;10	G;C;C	10;10;9	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	316	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	439	26.1	0	.	p	.	0	G319S	NONSYN	955	957	GGC	289	291	AGC	10;9;9	A;G;C	9;8;9	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	316	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	439	26.1	0	.	p	.	0	G320A	NONSYN	958	960	GGT	292	294	GCC	9;9;9	G;C;C	9;8;9	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	316	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	439	26.1	0	.	p	.	0	G322V	NONSYN	964	966	GGT	298	300	GTT	9;9;9	G;T;T	9;9;8	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2698	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1466	183.0	0	.	p	.	0	N38E	NONSYN	112	114	AAT	409	411	GAA	257;259;260	G;A;A	237;238;241	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2698	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1466	183.0	0	.	p	.	0	N134D	NONSYN	400	402	AAT	697	699	GAT	236;238;240	G;A;T	221;220;226	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2698	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1466	183.0	0	.	p	.	0	P175S	NONSYN	523	525	CCA	820	822	TCA	249;250;249	T;C;A	221;223;223	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2698	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1466	183.0	0	.	p	.	0	A218V	NONSYN	652	654	GCC	949	951	GTC	248;247;246	G;T;C	227;227;228	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2698	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1466	183.0	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1279	1281	GCA	153;153;150	G;C;A	134;133;131	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2698	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1466	183.0	0	.	p	.	0	D333V	NONSYN	997	999	GAC	1294	1296	GTC	136;138;137	G;T;C,A	117;119;118,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2698	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1466	183.0	1	SNP	p	G120K	1	.	.	358	360	AAG	655	657	AAG	242;239;244	A;A;G,T	224;222;225,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2698	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1466	183.0	1	SNP	p	A121D	1	.	.	361	363	GAC	658	660	GAC	245;243;243	G,A;A;C	226,1;225;225	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2698	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1466	183.0	1	SNP	p	D121N	0	.	.	361	363	GAC	658	660	GAC	245;243;243	G,A;A;C	226,1;225;225	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10882	rpoB	4179	4179	100.0	rpoB.l6.c30.ctg.1	4746	228.6	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1934	1936	AAT	235;234;230	A;A;T	215;213;212	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1214	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1034	116.4	1	SNP	p	V57M	1	.	.	169	171	ATG	515	517	ATG	235;233;231	A;T;G,A	212;212;208,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
